About this trial
Chronic lower back pain is a significant cause of disability, affecting 21-68% of people 60 years of age and older (source). Of these cases, 15-30% are attributed to posterior sacroiliac joint complex (PSIJC) pain (source), making it a target for treatment. Peripheral Nerve Stimulation (PNS) is a procedure that involves the placement of a lead under the skin with local anesthetic and electrically stimulating designated spinal nerves that deliver pain signals to the brain. It has emerged as a promising alternative to drug, injection, and radioablative therapies. Its use has been supported by previous studies of subjects who received permanent neurostimulation and experienced benefits such as decreased sensation of pain and perceived level of disability. SPRINT is a minimally invasive PNS system of interest due to its ability to provide long-term pain relief after temporary administration of PNS. The aim of this study is to understand whether the FDA-cleared SPRINT PNS system is safe and effective for the treatment of chronic PSIJC pain. This prospective clinical study will assess 10 subjects that meet the inclusion and exclusion criteria across 5 separate time points- 1.) Screening; 2.) Procedure within 3 months of screening; 3.) 12-day post-procedure follow-up; 4.) 3-month post-procedure follow-up; 5.) 3-Month post lead removal follow-up. The subjects will be required to complete physical examinations, and VAS and ODI questionnaires at timepoints 3, 4, and 5.
Eligibility criteria
Qualifiers
Sacroiliac pain as diagnosed above
Subject greater than 18 years old
Subject is severely debilitated by SIJ pain, with initial ODI score > 40%
Subject received conservative treatment for at least three months including physiotherapy and pain medication
Disqualifiers
Pregnancy
Subject is under the age of 18 years
Acute traumatic injury of the sacral iliac joint
Active inflammation or neoplastic infiltration of the SIJ
Trial design
Treatments tested in this trial
- SPRINT PNS System
Treatment groups
Sponsors and collaborators
Medical University of South Carolina
Lead sponsor
SPR Therapeutics, Inc.
Collaborator